drugset / Trial / NCT02302339
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will examine the effectiveness and safety of glembatumumab vedotin as monotherapy or in combination with immunotherapies in patients with advanced melanoma.
Timeline
- Start
- 2014-11
- Primary completion
- 2018-06-14
- Completion
- 2018-10-03
Outcome
Outcome not reported
Stopped: “Development of glembatumumab vedotin was discontinued”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CDX-301 | Protein / enzyme biologic | — | Other |
| Subject | Glembatumumab Vedotin | Other / unclassified | — | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Varlilumab | Monoclonal antibody | — | Intravenous |